Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)

Inclusion Criteria: * Male and female participants * Age 18-70 years * Malignant melanoma stage II or III (\>/= 1.5 mm tumor thickness, no distant metastases or Malignant melanoma with lymph node metastases or Lymph node metastases with unknown primary tumor * An excision border of at least 2 cm around the primary tumor * Therapy must start within 12 weeks after surgery of the tumor/of the lymph node metastases * ECOG status 0-1 (= Karnofsky Index \>/= 80) * Laboratory parameters * Hematocrit \>= 33% * Leukocytes \>= 3000/μl * Thrombocytes \>= 100000/μl * Alanine aminotransferase(ALT) \<= 2x normal values * Bilirubin \<= 2x normal values Exclusion Criteria: * Known allergy to one of the medications or any of its component parts * Refusal on the part of participants capable of childbearing to use a reliable contraceptive * Lactating mothers * Presence of distant metastases * Another primary tumor of different histological origin than corresponding to the indication (except when the relapse-free interval is \> 5 years, or the tumor is a cervical carcinoma in situ, a basal cell carcinoma or cutaneous squamous cell carcinoma) * Participants on corticosteroid treatment or treatment with an immunomodulating substance * Preexisting psychiatric illness, particularly serious depression * Prior adjuvant radio-, chemo-, or immuno-therapy * Treatment with an investigational drug within the prior 30 days * Participant history that includes cardiac arrhythmia, cardiac insufficiency requiring treatment, or anthracycline administration * Myocardial infarction within the prior year * An unstable medical condition (apart from the indication) that in the judgment of the investigating physician excludes the participants from the study * Psoriasis (a relative exclusion criterion, since interferon can aggravate psoriasis; decision to be based on risk/benefit analysis)